# 04_QA_REPORT.md
# QA Report — PP-0224 Peritoneal Carcinomatosis

## Identity

| Field | Value |
|---|---|
| PP ID | PP-0224 |
| Title | Peritoneal Carcinomatosis |
| QA Version | 1.0.0 |
| Production Version | 1.0.0 |
| Status | GOLD |
| Final Status | PASS — GOLD — READY FOR INTEGRATION |

## QA Scope

This QA report verifies PP-0224 against:

- the Approved + Locked Decision Batch;
- CORE_WORKING_RULES v1.7;
- FREEZE GOLD POPULATION PACKAGE SPECIFICATION;
- approved Gold Discussion reference;
- supplied gastric-cancer clinical materials;
- PP Registry;
- adjacent PP ownership;
- absolute Gold-depth requirements.

## Layer 1 — Content QA

### Atomic Question

**PASS**

The package answers one atomic clinical educational question: what peritoneal carcinomatosis is, how it is characterized, what it can cause, and why it matters.

### Scope Coverage

**PASS**

The package covers:

- definition;
- relationship to peritoneal metastasis;
- conceptual biology;
- visible disease;
- cytology;
- laparoscopy;
- washings;
- PCI;
- symptoms;
- ascites;
- disease burden;
- prognosis;
- systemic-treatment architecture;
- cytoreduction;
- multidisciplinary assessment;
- HIPEC/PIPAC boundary;
- patient-facing misconceptions.

### Scope Restraint

**PASS**

The package does not absorb:

- dedicated peritoneal-only treatment;
- HIPEC evidence package;
- detailed PCI scoring;
- surgical technique;
- detailed systemic therapy;
- detailed palliative procedures.

## Layer 2 — Clinical QA

### Definition Audit

**PASS**

Peritoneal carcinomatosis is presented as a manifestation of gastric-cancer spread rather than a new primary cancer.

### Staging Audit

**PASS**

Positive peritoneal cytology is correctly represented as M1 disease in the supplied NCCN framework. fileciteturn31file13

### Diagnostic Audit

**PASS**

CT, selected PET/CT, diagnostic laparoscopy, washings and biopsy are represented at appropriate conceptual levels.

### Imaging Limitation Audit

**PASS**

The package explicitly avoids claiming that negative imaging excludes all peritoneal disease.

### PCI Audit

**PASS**

PCI is described as a structured measure of disease extent.

The package does not turn PCI into a standalone treatment rule.

### Treatment Architecture Audit

**PASS**

Systemic therapy is represented as a management component without regimen-level duplication.

### Cytoreduction Audit

**PASS**

Cytoreduction is presented as selected and dependent on feasibility rather than automatic.

### HIPEC Audit

**PASS**

HIPEC is described as specialized and selective.

NCCN's requirement for selected circumstances and multidisciplinary discussion is preserved. fileciteturn31file14turn31file18

### PIPAC Audit

**PASS**

PIPAC is correctly identified as investigational within the supplied NCCN framework. fileciteturn31file14

## Layer 3 — Educational QA

### Plain-language audit

**PASS**

Technical terms are explained at first use.

### Patient-facing depth

**PASS**

The package contains:

- patient questions;
- myths/facts;
- clinical reasoning model;
- symptom explanations;
- test explanations;
- safety boundary.

### Misconception Audit

**PASS**

The package explicitly corrects:

- peritoneal disease as a new cancer;
- negative CT as absolute exclusion;
- positive cytology requiring visible implants;
- PCI as a standalone treatment rule;
- peritoneal disease as untreatable;
- universal HIPEC;
- ascites as automatically malignant.

### Uncertainty Audit

**PASS**

Context-dependent and investigational concepts are labeled.

## Layer 4 — Governance QA

### Source-First Rule

**PASS**

PP-specific clinical source materials were searched before artifact synthesis.

### Governance Rule

**PASS**

CORE_WORKING_RULES and Gold Specification were reviewed.

### Gold Discussion Rule

**PASS**

The approved Discussion depth/format example was used as the structural and reasoning-depth reference. The example requires a complete Decision Batch and substantive evidence/boundary reasoning rather than a short summary. fileciteturn30file2turn30file14

### User-Controlled Sequence

**PASS**

PP-0224 was produced only because the Project Coordinator explicitly requested and subsequently approved/locked it.

### Immediate Production Rule

**PASS**

Production followed immediately after approval/lock, without reopening format/depth/package questions.

## Clinical Safety Review

| Safety Check | Result |
|---|---|
| Individual diagnosis | PASS — not provided |
| Individual treatment prescription | PASS — not provided |
| HIPEC eligibility | PASS — not determined |
| Individual PCI interpretation | PASS — not determined |
| Individual prognosis | PASS — not provided |
| Drug dosing | PASS — not provided |
| Treatment switching | PASS — not prescribed |
| Biomarker-driven treatment | PASS — delegated |
| Imaging interpretation | PASS — not individualized |
| Surgical recommendation | PASS — not individualized |

## Patient Misconception Review

### Misconception: “Peritoneal carcinomatosis is a new abdominal cancer.”

**PASS — corrected.**

### Misconception: “CT negative means no peritoneal disease.”

**PASS — corrected.**

### Misconception: “No visible implants means cytology cannot be positive.”

**PASS — corrected.**

### Misconception: “PCI alone decides treatment.”

**PASS — corrected.**

### Misconception: “Peritoneal disease means no treatment.”

**PASS — corrected.**

### Misconception: “HIPEC is for everyone.”

**PASS — corrected.**

### Misconception: “Ascites automatically means malignant peritoneal disease.”

**PASS — corrected.**

## Adjacent PP Overlap Audit

### PP-0048 — Peritoneal Metastasis

**Ownership:** foundational peritoneal-metastasis concept.

**PP-0224:** deeper clinical disease-state characterization.

**Result: PASS — specialization, not duplication.**

### PP-0223 — Metastatic Gastric Cancer

**Ownership:** overall metastatic disease.

**PP-0224:** peritoneal-specific disease state.

**Result: PASS.**

### PP-0225 — Peritoneal Carcinoma as Only Disease

**Ownership:** dedicated peritoneal-only treatment pathway.

**PP-0224:** general peritoneal carcinomatosis, regardless of whether other metastatic disease is present.

**Result: PASS.**

### PP-0226 — HIPEC

**Ownership:** HIPEC/intraperitoneal-treatment detail.

**PP-0224:** HIPEC context and boundary only.

**Result: PASS.**

### PP-0217–0219

**Ownership:** response assessment, RECIST, post-treatment imaging.

**PP-0224:** reassessment concept only.

**Result: PASS.**

### PP-0227–0228

**Ownership:** palliative and best-supportive-care detail.

**PP-0224:** symptom and supportive-care interface.

**Result: PASS.**

### PP-0231

**Ownership:** treatment toxicity/supportive-care detail.

**PP-0224:** nutritional/symptom context only.

**Result: PASS.**

### PP-0232

**Ownership:** detailed multidisciplinary management.

**PP-0224:** why MDT matters for peritoneal disease.

**Result: PASS.**

## Evidence Traceability Audit

| Evidence Area | Traceable | Result |
|---|---|---|
| M1 / positive cytology | NCCN v2.2026 | PASS |
| Laparoscopy | NCCN v2.2026 | PASS |
| Washings | NCCN v2.2026 | PASS |
| PCI | NCCN v2.2026 | PASS |
| Peritoneal-only pathway | NCCN v2.2026 | PASS |
| Cytoreduction | NCCN v2.2026 | PASS |
| HIPEC selection | NCCN v2.2026 | PASS |
| PIPAC investigational status | NCCN v2.2026 | PASS |
| Patient-facing HIPEC context | NCI | PASS |

## Numerical Evidence Audit

The package uses the guideline-supported PCI categories:

- PCI ≤10;
- PCI >10.

These are presented as **contextual disease-burden categories**, not as standalone eligibility rules.

No unsupported survival estimate is presented.

No individualized probability is presented.

**Result: PASS.**

## Knowledge Graph Audit

### Prerequisites

**PASS**

PP-0046, PP-0047, PP-0048, PP-0008, PP-0027 and PP-0223 are identified.

### Related

**PASS**

Response assessment, systemic therapy and MDT relationships are identified.

### Downstream

**PASS**

PP-0225, PP-0226, PP-0227, PP-0228, PP-0231 and PP-0232 are identified.

### Artificial relationships

**PASS**

No relationship is included solely to fill a mandatory section.

## Gold Depth Integrity Review

The Gold standard states that future PPs must not be compacted or materially reduced relative to approved Gold references and that additional depth is allowed when supported by scope/evidence. fileciteturn30file19

### CKO

**PASS**

Contains:

- metadata;
- atomic question;
- objectives;
- included/excluded scope;
- four-part boundary;
- extensive clinical knowledge blocks;
- patient questions;
- misconceptions;
- clinical reasoning;
- safety boundary;
- Knowledge Graph;
- key messages;
- revision history.

### Knowledge Passport

**PASS**

Contains:

- identity;
- classification;
- runtime use;
- retrieval terms;
- patient journey;
- scope;
- knowledge units;
- evidence maturity;
- evidence hierarchy;
- routing rules;
- boundary ownership matrix;
- Knowledge Graph;
- governance metadata;
- final runtime principle.

### Primary Evidence Package

**PASS**

Contains:

- identity;
- clinical question;
- educational intent;
- scope;
- primary/supporting sources;
- evidence hierarchy;
- detailed evidence matrix;
- detailed evidence appraisal;
- clinical claims;
- consistency review;
- evidence limitations;
- evidence gaps;
- maturity map;
- patient translation;
- boundary verification;
- Knowledge Graph;
- source traceability;
- update triggers.

### QA Report

**PASS**

Contains substantive:

- Layer 1 Content QA;
- Layer 2 Clinical QA;
- Layer 3 Educational QA;
- Layer 4 Governance QA;
- clinical safety;
- misconception review;
- overlap audit;
- evidence traceability;
- numerical evidence audit;
- Knowledge Graph audit;
- Gold-depth audit;
- Source-First audit;
- locked-decision integrity;
- cross-artifact consistency;
- package integrity.

**Gold-depth result: PASS.**

## Source-First Audit Log

### Step 1 — PP-specific clinical materials

**PASS**

NCCN v2.2026 was identified as the primary direct source, with NCCN v2.2025 and NCI materials as supporting sources.

### Step 2 — Governance

**PASS**

CORE_WORKING_RULES v1.7 and FREEZE GOLD POPULATION PACKAGE SPECIFICATION were reviewed.

### Step 3 — Gold Discussion reference

**PASS**

PP Discussion depth and format example was reviewed.

### Step 4 — Registry / adjacent PP architecture

**PASS**

PP Registry confirms:

- PP-0048 Peritoneal Metastasis;
- PP-0223 Metastatic Gastric Cancer;
- PP-0224 Peritoneal Carcinomatosis;
- PP-0225 Peritoneal Carcinoma as Only Disease;
- PP-0226 HIPEC.

The registry explicitly describes PP-0048 as foundational and PP-0225/0226 as downstream topics. fileciteturn31file0

### Step 5 — Approved Decision

**PASS**

The Project Coordinator explicitly approved and locked the PP-0224 Decision Batch.

### Step 6 — Production

**PASS**

Four Gold artifacts produced and packaged as one ZIP.

## Locked Decision Integrity

**PASS**

No scope reopening occurred during artifact production.

No new competing PP ownership was created.

No downstream treatment package was absorbed.

## Cross-artifact Consistency

| Dimension | Result |
|---|---|
| PP ID | PASS |
| Title | PASS |
| Version | PASS |
| Atomic question | PASS |
| Scope | PASS |
| Boundary | PASS |
| Evidence hierarchy | PASS |
| Knowledge Graph | PASS |
| Safety language | PASS |
| Final status | PASS |

## Package Integrity

Expected artifacts:

1. `01_CKO.md`
2. `02_KNOWLEDGE_PASSPORT.md`
3. `03_PRIMARY_EVIDENCE_PACKAGE.md`
4. `04_QA_REPORT.md`

**All four present.**

No temporary files included.

## Final QA Decision

| QA Layer | Result |
|---|---|
| Content QA | PASS |
| Clinical QA | PASS |
| Educational QA | PASS |
| Governance QA | PASS |
| Clinical Safety | PASS |
| Misconception Review | PASS |
| Adjacent PP Overlap | PASS |
| Evidence Traceability | PASS |
| Numerical Evidence | PASS |
| Knowledge Graph | PASS |
| Gold Depth Integrity | PASS |
| Source-First | PASS |
| Locked Decision Integrity | PASS |
| Cross-artifact Consistency | PASS |
| Package Integrity | PASS |

# PASS — GOLD — READY FOR INTEGRATION

## Revision History

| Version | Date | Summary |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA after Approved + Locked Decision Batch. |
